TY - JOUR
T1 - A New Fluorescent Method to Detect Sulfamidase Activity in Blood, Tissue Extracts and Dried Blood Spots
AU - He, Xingxuan
AU - Schuchman, Edward H.
AU - Simonaro, Calogera M.
N1 - Publisher Copyright:
© 2021, Latin American Society Inborn Errors and Neonatal Screening. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Mucopolysaccharidosis type IIIA (MPS IIIA) is a lysosomal storage disorder due to the deficient activity of sulfamidase (SGSH). Traditionally, measurement of this enzymatic activity has been performed using a fluorescently (4-MU) labeled glycoside substrate. While this substrate is inexpensive and readily available, the current method requires a 2-step procedure that is performed over 2 days. Here we report a new and simplified procedure using the 4-MU substrate. Major advantages of this assay method over the existing fluorescent method include a single step vs. 2-step procedure, an incubation time of 1 hour, and high sensitivity. The reaction is also run on UPLC equipment, which is available in most research labs and permits separation of the endogenous, autofluorescent material from the 4-MU signal. This assay method was developed using the MPS IIIA mouse model, and was validated using mouse plasma, liver and brain extracts, and dried blood spots. Human MPS IIIA skin fibroblasts and dried blood spots also were used to validate the method.
AB - Mucopolysaccharidosis type IIIA (MPS IIIA) is a lysosomal storage disorder due to the deficient activity of sulfamidase (SGSH). Traditionally, measurement of this enzymatic activity has been performed using a fluorescently (4-MU) labeled glycoside substrate. While this substrate is inexpensive and readily available, the current method requires a 2-step procedure that is performed over 2 days. Here we report a new and simplified procedure using the 4-MU substrate. Major advantages of this assay method over the existing fluorescent method include a single step vs. 2-step procedure, an incubation time of 1 hour, and high sensitivity. The reaction is also run on UPLC equipment, which is available in most research labs and permits separation of the endogenous, autofluorescent material from the 4-MU signal. This assay method was developed using the MPS IIIA mouse model, and was validated using mouse plasma, liver and brain extracts, and dried blood spots. Human MPS IIIA skin fibroblasts and dried blood spots also were used to validate the method.
KW - Mucopolysaccharidosis type IIIA
KW - Sanfilippo Syndrome
KW - diagnostic assay
KW - sulfamidase
UR - http://www.scopus.com/inward/record.url?scp=85119867173&partnerID=8YFLogxK
U2 - 10.1590/2326-4594-JIEMS-2020-0021
DO - 10.1590/2326-4594-JIEMS-2020-0021
M3 - Article
AN - SCOPUS:85119867173
SN - 2326-4098
VL - 9
JO - Journal of Inborn Errors of Metabolism and Screening
JF - Journal of Inborn Errors of Metabolism and Screening
M1 - e20200021
ER -